NDC Compounded Drug 72196-0012-2 Aspartic Acid; Glutamic Acid; Citric Acid Monohydrate; Trisodium Citrate Dihydrate; Sodium Phosphate, Monobasic, Monohydrate; Anhydrous Dextrose

Solution Intracoronary

Table of Contents

    1. Compounded Product Information
    2. Frequently Asked Questions

Compounded Drug Product Information

NDC Product Code 72196-0012
NDC Package Code 72196-0012-2
11-Digit NDC Billing Format NDC Format for Billing
For insurance billing purposes the Centers for Medicare & Medicaid Services (CMS) created an 11 digit NDC derivative identifier. If the NDC Package code is less than 11 digits the code must be padded with leading zeros. The leading zeros must be added to the appropriate segment to create a 5-4-2 configuration.		 72196001202
Package Description 120 mL in 1 BAG
Product Type What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.		 Human Compounded Drug
Proprietary Name What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.		 Microplegia (msa/msg 0.92 Molar) With Cp2d
Non-Proprietary Name What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.		 Microplegia (msa/msg 0.92 Molar) With Cp2d
Substance Name What is the Substance Name?
An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.		 Aspartic Acid; Glutamic Acid; Citric Acid Monohydrate; Trisodium Citrate Dihydrate; Sodium Phosphate, Monobasic, Monohydrate; Anhydrous Dextrose
Dosage Form Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Route Name Intracoronary - Administration within the coronary arteries.
Marketing Category OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Code 72196
Labeler Name What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.		 Central Admixture Pharmacy Services, Inc.
Substance Name Aspartic Acid; Glutamic Acid; Citric Acid Monohydrate; Trisodium Citrate Dihydrate; Sodium Phosphate, Monobasic, Monohydrate; Anhydrous Dextrose
Active Ingredients Information .03769 g/1 mL; .04206 g/1 mL; .01226 g/1 mL; .09863 g/1 mL; .00833 g/1 mL; .174 g/1 mL
Reporting Period 2023-2

Frequently Asked Questions

What is the NDC number assigned to Microplegia (msa/msg 0.92 Molar) With Cp2d?

Microplegia (msa/msg 0.92 Molar) With Cp2d was assigned by its manufacturer with NDC product code 72196-0012. This product is a drug classified as a human compounded drug. Compounded drugs are medications created by combining or altering existing drugs to meet the specific needs of certain patients. The NDC directory only includes information about compounded drugs from facilities that choose to assign NDC numbers to their products.

Which are the NDC package codes for Microplegia (msa/msg 0.92 Molar) With Cp2d?

The NDC package code 72196-0012-2 was assigned to a 120 mL in 1 BAG of aspartic acid; glutamic acid; citric acid monohydrate; trisodium citrate dihydrate; sodium phosphate, monobasic, monohydrate; anhydrous dextrose administered intracoronary via solution.

Who manufactures this product?

Microplegia (msa/msg 0.92 Molar) With Cp2d is manufactured by an outsourced facility and labeled by Central Admixture Pharmacy Services, Inc.. All compounded drugs included in the NDC directory are classified as "Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)". Outsourcing facilities are a type of drug compounding facility regulated under Section 503B of the FD&C Act could be eligible for exemptions from drug registration if they meet all the conditions specified under Section 503B.